# EDGAR Filing Document

**Accession Number:** 0000875657
**File Stem:** 0001437749-23-004092
**Filing Date:** 2023-2
**Character Count:** 10545
**Document Hash:** 32d823c18a130e78175da1a4327ceff0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-004092.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001437749-23-004092

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230221

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ULTRALIFE CORP
- **CENTRAL INDEX KEY:** 0000875657
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
- **IRS NUMBER:** 161387013
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-20852
- **FILM NUMBER:** 23651047

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 TECHNOLOGY PARKWAY
- **CITY:** NEWARK
- **STATE:** NY
- **ZIP:** 14513
- **BUSINESS PHONE:** 3153327100

**MAIL ADDRESS:**
- **STREET 1:** 2000 TECHNOLOGY PARKWAY
- **CITY:** NEWARK
- **STATE:** NY
- **ZIP:** 14513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ULTRALIFE BATTERIES INC
- **DATE OF NAME CHANGE:** 19940224

ulbi20230221_8k.htm

---

| | | |
|:---|:---|:---|
| **UNITED STATES** | **UNITED STATES** | **UNITED STATES** |
| **SECURITIES AND EXCHANGE COMMISSION** | **SECURITIES AND EXCHANGE COMMISSION** | **SECURITIES AND EXCHANGE COMMISSION** |
| **Washington, D.C. 20549** | **Washington, D.C. 20549** | **Washington, D.C. 20549** |
| **FORM **8-K** | **FORM **8-K** | **FORM **8-K** |
| **CURRENT REPORT**<br> **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** | **CURRENT REPORT**<br> **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** | **CURRENT REPORT**<br> **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** |
| **February 21, 2023** | **February 21, 2023** | **February 21, 2023** |
| Date of Report (Date of Earliest Event Reported) | Date of Report (Date of Earliest Event Reported) | Date of Report (Date of Earliest Event Reported) |
| **ULTRALIFE CORPORATION** | **ULTRALIFE CORPORATION** | **ULTRALIFE CORPORATION** |
| (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) |
| **Delaware** | **000-20852** | **16-1387013** |
| (State of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| **2000 Technology Parkway, **Newark**, **New York 14513** | **2000 Technology Parkway, **Newark**, **New York 14513** | **2000 Technology Parkway, **Newark**, **New York 14513** |
| (Address of principal executive offices) (Zip Code) | (Address of principal executive offices) (Zip Code) | (Address of principal executive offices) (Zip Code) |
| **(**315**) **332-7100** | **(**315**) **332-7100** | **(**315**) **332-7100** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **Common Stock, $0.10 par value per share** | **ULBI** | **NASDAQ** |
| (Title of each class) | (Trading Symbol) | (Name of each exchange on which registered) |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |

---

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointments of Certain Officers; Compensatory Arrangement of Certain Officers**

On February 21, 2023, the Board of Directors (the "Board") of Ultralife Corporation (the "Company") appointed Janie Goddard as an independent director of the Company effective as of February 21, 2023.

Most recently, Ms. Goddard has served as a Divisional Chief Executive for the Environmental & Analysis Sector at Halma plc. Before joining Halma, Ms. Goddard served as Divisional President of the Detection & Analysis Business Unit at Novanta, where she led a portfolio of solutions for medical device OEMs. Prior to Novanta, Ms. Goddard served in leadership roles at Welch Allyn (acquired by Hill-Rom), Covidien (acquired by Medtronic), and Johnson & Johnson. Ms. Goddard also serves on the board of directors of Methode Electronics, Inc., a public company (NYSE: MEI) that develops and manufactures custom solutions for the transportation (including electric vehicles), industrial and medical markets. She received a B.S. in Business Administration from Washington University in St. Louis and an M.B.A. from Harvard Business School

Ms. Goddard will receive the standard compensation payable to non-employee directors of the Company, which is described in the Company's 2022 proxy statement filed with the U.S. Securities and Exchange Commission on May 31, 2022. Ms. Goddard will serve on the following committees of the Board: Audit & Finance Committee, Compensation & Management Committee, and Corporate Development & Governance Committee.

There is no arrangement or understanding between Ms. Goddard and any other person pursuant to which she was selected as a director. Ms. Goddard has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

**Item 7.01 Regulation FD Disclosure**

On February 22, 2023, the Company issued a press release announcing the appointment of Janie Goddard as an independent director of the Company. A copy of the press release is furnished as Exhibit 99.1 attached hereto.

**Item 9.01 Financial Statements, Pro Forma Financials and Exhibits**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** |
| 99.1 | [Press Release of Ultralife Corporation dated February 22, 2023](ex_478848.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 22, 2023 |  | **ULTRALIFE CORPORATION** |
|  | By: | /s/ Philip A. Fain |
|  |  | Philip A. Fain |
|  |  | Chief Financial Officer and Treasurer |

---

## Exhibit 99.1

**Exhibit 99.1**

![ex_478848img001.jpg](ex_478848img001.jpg)

**Ultralife Corporation Adds Janie Goddard to its Board of Directors**

NEWARK, N.Y. February 22, 2023 – Ultralife Corporation (NASDAQ: ULBI) announced today the addition of Janie Goddard as Director of the Company.

Chairman Bradford Whitmore said, "We are pleased to welcome Janie to our Board of Directors and look forward to leveraging her extensive business career. Janie is an experienced, results-driven executive who brings a strong track record of P&L leadership within global companies and a background in commercial execution, strategic marketing, and product development. Her depth and breadth of experience in global medical device and industrial markets will add significant perspective in the support of Ultralife's growth strategy."

Most recently, Ms. Goddard has served as a Divisional Chief Executive for the Environmental & Analysis Sector at Halma plc. Before joining Halma, Ms. Goddard served as Divisional President of the Detection & Analysis Business Unit at Novanta, where she led a portfolio of solutions for medical device OEMs. Prior to Novanta, Ms. Goddard served in leadership roles at Welch Allyn (acquired by Hill-Rom), Covidien (acquired by Medtronic), and Johnson & Johnson. Ms. Goddard also serves on the board of directors of Methode Electronics, Inc., a public company (NYSE: MEI) that develops and manufactures custom solutions for the transportation (including electric vehicles), industrial and medical markets. She received a B.S. in Business Administration from Washington University in St. Louis and an M.B.A. from Harvard Business School.

**About Ultralife Corporation**

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include: Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit <u>http://www.ultralifecorporation.com</u>.

---

| |
|:---|
| **Company Contact:** |
| Ultralife Corporation |
| Philip A. Fain |
| (315) 210-6110 |
| <u>pfain@ulbi.com</u> |
| **Investor Relations Contact:** |
| LHA |
| Jody Burfening |
| (212) 838-3777 |
| jburfening@lhai.com |

---